There are no ongoing patient studies with cinaciguat,31 but there are 9 actively recruiting studies on riociguat in scleroderma, sickle cell disease, PAH, and chronic thromboembolic pulmonary hypertension.32 As seen from our research, the sGC activators have profound and partly unphysiological effects demanding considerable preclinical assessments before clinical application. Here, SGCB is linked to scleroderma.